Search results
Results from the WOW.Com Content Network
Isoprenaline is used to treat heart block and episodes of Adams–Stokes syndrome that are not caused by ventricular tachycardia or fibrillation, in emergencies for cardiac arrest until electric shock can be administered, for bronchospasm occurring during anesthesia, and as an adjunct in the treatment of hypovolemic shock, septic shock, low cardiac output (hypoperfusion) states, congestive ...
Many patients with MRONJ have successful outcomes after treatment, [50] meaning that the local osteonecrosis is stopped, the infection is cleared, and the mucosa heals and once again covers the bone. The treatment the person receives depends on the severity of osteonecrosis of the jaw.
The conclusions are that it is an effective treatment for full thickness chondral defects. The evidence does not suggest ACI is superior to other treatments. [3] One ACI treatment, called MACI (autologous cultured chondrocytes on a porcine collagen matrix), is indicated for healthy patients 18–55 with medium to large sized damage to their ...
Senile osteoporosis has been recently recognized as a geriatric syndrome with a particular pathophysiology. There are different classification of osteoporosis: primary, in which bone loss is a result of aging and secondary, in which bone loss occurs from various clinical and lifestyle factors. [1]
Strontium ranelate, a strontium(II) salt of ranelic acid, is a medication for osteoporosis marketed as Protelos or Protos by Servier. Studies indicate it can also slow the course of osteoarthritis of the knee. [1] The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by ...
The knee is one of the joints most commonly affected by osteoarthritis. [2] Cartilage in the knee may begin to break down after sustained stress, leaving the bones of the knee rubbing against each other and resulting in osteoarthritis. [7] Nearly a third of US citizens are affected by osteoarthritis of the knee by age 70. [8]
The Royal Osteoporosis Society supports ground-breaking and pioneering research aimed at improving the prevention, diagnosis treatment of osteoporosis. The charity has invested over £5 million in more than 130 projects which have enhanced knowledge and understanding of osteoporosis, leading to significant improvements in diagnosis and treatment.
Odanacatib (INN; [1] codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis. [2] It is an inhibitor of cathepsin K , [ 3 ] an enzyme involved in bone resorption . The drug was developed by Merck & Co.